Pancreatectomy for adenocarcinoma: Prognostic factors, recommandations for pathological reports;Pancréatectomie pour adénocarcinome: Facteurs pronostiques, recommandations de rédaction des comptes-rendus

Annales de Pathologie

Volumn 22, Issue 5, 2002, Pages 422-432

  Chatelaín, Denis ^a   Fléjou, Jean François ^b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Pancreatectomy; Pancreatic adenocarcinoma; Pathological report; Prognostic factors

Indexed keywords

ARTICLE; HUMAN; LYMPH NODE METASTASIS; MESENTERIC ARTERY; MESENTERIC VEIN; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PORTAL VEIN; SURGICAL TECHNIQUE; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; FOLLOW-UP STUDIES; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0036812643     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Queneau PE, Pitard A, Labourey JM, Koch S, Sauve G, Carayon P. Évolution de la prise en charge de l'adénocarcinome pancréatique dans une série hospitalière (1980-1994). Gastroenterol Clin Biol 2000; 24: 501-5.
2. Gudjonsson B. Carcinoma of the pancreas: Critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg 1995; 181: 483-503.
3. Kuvshinoff BW, Bryer MP. Treatment of resectable and locally advanced pancreatic cancer. Cancer Control 2000; 7: 428-36.
4. Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Forestieri P et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 2000; 73: 212-8.
5. Solcia E, Capella C, Klöppel G. Atlas of Tumor Pathology, Tumors of the Pancreas, Third Series, Fascicle 20. Washington DC: Armed Forces Institute of Pathology, 1997; 64-92 et 253-7.
6. Tsiotos GG, Farnell MB, Sarr MG. Are the results of pancreatectomy for pancreatic cancer improving? World J Surg 1999; 23: 913-9.
7. Slavin J, Ghaneh P, Jones L, Sutton R, Hartley M, Neoptolemos JP. The future of surgery for pancreatic cancer. Ann Oncol 1999; 10: S285-90.
8. Lüttges J, Vogel I, Menke M, Henne-Bruns D, Kremer B, Klöppel G. The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch 1998; 433: 237-42.
9. t Louis, volume two, appendix H, Pancreas-Pancreatectomy, 1996; 2690-1.
10. Hruban RH, Phelps TH, Westra WH, Isaacson C. Surgical Pathology Dissection. The Pancreas; Springer-Verlag New York, 1996; 72-6.
11. è Èdition, Springer-Verlag France, 1998, p 136-152.
12. Compton CC, Henson DE. Protocol for the examination of specimens removed from patients with carcinoma of the exocrine pancreas. Arch Pathol Lab Med 1997; 121: 1129-35.
13. Meyer W, Jurowich C, Steinhäuser B, Wünsch PH, Gebhardt C. Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas. Surg Today 2000; 30: 582-7.
14. Sperti C, Bonadimani B, Pasquali C, Piccoli A, Capepellazzo F, Rugge M et al. Ductal adenocarcinoma of the pancreas: Clinicopathologic features and survival. Tumori 1993; 79: 325-30.
15. Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996; 223: 147-53.
16. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68-73.
17. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN et al. Pancreaticoduodenectomy for cancer of the head of the pancreas 201 patients. Ann Surg 1995; 6: 721-33.
18. Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM, Christein JD, Doolas A et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999; 65: 618-24.
19. Magistrelli P, Antinori A, Crucitti A, La Greca A, Masetti R, Coppola R et al. Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol 2000; 74: 36-40.
20. Ahmad NA, Lewis JD, Ginsberg GG, Haller DG, Morris JB, Williams NN et al. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol 2001; 96: 2609-15.
21. Nagakawa T, Nagamori M, Futakami Y, Kayahara M, Ohta T, Ueno K et al. Results of extensive surgery for pancreatic carcinoma. Cancer 1996; 77: 640-5.
22. Takahashi T, Ishikura H, Motohara T, Okushiba SI, Dohke M, Katoh H. Perineural invasion by ductal adenocarcinoma of the pancreas. J Surg Oncol 1997; 65: 164-70.
23. Yamaguchi K, Enjoji M. Carcinoma of the pancreas: A clinicopathologic study of 96 cases with immunohistochemical observations. Jpn J Clin Oncol 1989; 19: 14-22.
24. Baumel H, Huguier M, Manderscheid JC, Fabre JM, Houry S, Fagot H. Results of resection for cancer of the exocrine pancreas: A study from the french association of surgery. Br J Surg 1994; 81: 102-7.
25. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161: 120-4.
26. Hermanek P. Staging of exocrine pancreatic carcinoma. Eur J Surg Oncol 1991; 17: 167-72.
27. Adsay V, Pierson C, Sarkar F, Abrams J, Weaver D, Conlon KC et al. Colloid (mucinous noncystic carcinoma) of the pancreas. Am J Surg Pathol 2001; 25: 26-42.
28. Fukushima N, Mukai K, Sakamoto M, Hasebe T, Shimada K, Kosuge T et al. Invasive carcinoma derived from intraductal papillary-mucinous carcinoma of the pancreas: Clinicopathologic and immunohistochemical study of eight cases. Virchows Arch 2001; 439: 6-13.
29. Klöppel G, Lindenthal G, von Bülow M, Kern HF. Histological and fine structural features of pancreatic ductal adenocarcinoma in relation to growth and prognosis: Studies in xenografted tumours and clinico-histopathological correlation in a series of 75 cases. Histopathology 1985; 9: 841-56.
30. Tannapfel A, Wittekind C, Hünefeld G. Ductal adenocarcinoma of the pancreas. Int J Pancreatol 1992; 12: 145-52.
31. Sarmiento JM, Nagorney DM, Sarr MG, Farnell MB. Periampullary cancers. Are there differences? Surg Clin North Am 2001; 81: 543-55.
32. Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control 2000; 7: 421-7.
33. Makinen K, Hakala T, Lipponen P, Alhava E, Eskelinen M. Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res 1998; 18: 615-8.
34. Expression of Bcl-2 and p53 protein in respectable invasive ductal carcinoma of the pancreas: Effects on clinical outcome and efficacy of adjuvant chemotherapy. J Surg Oncol 2001; 76: 188-96.
35. Gansauge S, Gansauge F, Ramdani M, Stobbe H, Rau B, Harada N et al. Overexpression of cyclin DI in human pancreatic cancer is associated with poor prognosis. Cancer Res 1997; 57: 1634-37.
36. Ahrendt SA, Brown HM, Komorowski RA, Zhu YR, Wilson SD, Erickson BA et al. p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. Surgery 2000; 128: 520-30.
37. Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16 (INK4A), p21 (WAF-1), cyclin D1, erbB-2, and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000; 89: 469-74.
38. Lu CD, Morita S, Ishibashi T, Hara H, Isozaki H, Tanigawa N. Loss of p27Kip1 expression independently predicts poor prognosis for patients with respectable pancreatic adenocarcinoma. Cancer 1999; 85: 1250-60.
39. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Okai T et al. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 1997; 3: 1473-7.
40. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001; 7: 4115-21.
41. Coppola D, Lu L, Fruehauf JP, Kyshtoobayeva A, Karl RC, Nicosia SV et al. Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival. Am J Clin Pathol 1998; 110: 16-23.
42. Takahashi S, Hasebe T, Oda T, Sasaki S, Kinoshita T, Konishi M et al. Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer 2002; 94: 1894-901.
43. Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R et al. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Pathol 2001; 24: 447-52.
44. Nio Y, Iguchi C, Yamasawa K, Sasaki S, Takamura M, Toga T et al. Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas. Pancreas 2001; 22: 230-9.
45. Takahashi S, Hasebe T, Oda T, Sasaki S, Kinoshita T, Konishi M et al. Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer 2002; 94: 1894-901.
46. Bottger T, Maschek H, Gottwald W, Lobo M, Brenner W, Junginger T. Expression of CD44 and isoforms v4, v5, v6, v7, v10, new prognostic parameters in ductal pancreatic carcinoma? Chirurg 1998; 10: 1089-92.
47. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: Clinicopathologic and prognostic significance of matrylisin expression. J Clin. Oncol 2001; 19: 1118-27.
48. Ito T, Ito M, Shiozawa J, Naito S, Kanematsu T, Sekine 1. Expression of the MMP-1 in human pancreatic carcinoma: Relationship with prognostic factor. Mod Pathol 1999; 12: 669-74.
49. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000; 88: 2239-45.
50. Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur. J Cancer 1998; 34: 337-40.
51. Balzano G, Bassi C, Zerbi A, Falconi M, Calori G, Butturini G et al. Evaluation of UICC TNM classification for pancreatic cancer. Int J Pancreatol 1997; 21: 111-8.
52. Hamilton SR, Aaltonen LA. World Health Organization. International Histological Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. IARC Press, Lyon 2000; 220.